tirzepatide alzheimer clinical trial Potential Alzheimer's treatment, trontinemab, hits the news – how does it work and is it available? Weight-loss drug tirzepatide may lower

Am J Med

Yes, switching is a legitimate strategy

In head-to-head data, tirzepatide at 15mg produced roughly 22.5% body weight loss compared to semaglutide at 2.4mg producing roughly 15% body weight loss

Baseline population: 45 years old on average, 65% female, BMI 39, mean weight 113 kg, 16 years of obesity history

You can use the same area of your body each week if you want to

You can read the abstract of this article at In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide demonstrated superior reductions in HbA1c concentrations, bodyweight, and blood pressure compared to titrated daily insulin glargine in individuals with type 2 diabetes and cardiovascular risk